Previously, we developed a prognostic biomarker model containing five DNA methylation markers (GREM1, GATA5, LAD1, NEFH, and NEURL) in combination with clinicopathological characteristics including age at diagnosis, sex, Fuhrman grade, tumor size, and TNM 3rd edition staging system. Here, GATA5 is linked to neoplasm.